Top Story Today
Lilly Hands Psychedelic Medicine the Keys to the House With a $3.8B Deal
Eli Lilly is acquiring AtaiBeckley for up to $3.8 billion ($2.8B upfront, $1B in milestones), making it the largest Big Pharma acquisition ever for a psychedelic-mechanism drug. The crown jewel is BPL-003, a nasal spray based on 5-MeO-DMT for treatment-resistant depression that already has FDA Breakthrough Therapy designation and nailed all endpoints in Phase 2. A single spray produced antidepressant effects within two days that held for eight weeks, with sessions lasting just two hours versus six-plus for psilocybin therapies. Two Phase 3 trials are underway, with results expected by early 2029.
Why it matters: Wall Street analysts are calling this a turning point for the entire psychedelic medicine field. If a company worth hundreds of billions is writing a check this large for a psychedelic drug, the stigma around this therapeutic class is officially lifting, and competitors like Compass Pathways stand to benefit from the validation.
Read more →Deals and Strategy
GSK Beats Estimates, Then Drops a $2.5 Billion Demolition Plan
GSK posted Q2 sales of 8.4 billion pounds (beating consensus by 2%), then announced a three-year restructuring to strip out 1.9 billion pounds in annual costs by 2029. The real motive: bridging the 2028 patent cliff when blockbuster HIV drug dolutegravir loses exclusivity. Most savings are flowing straight back into R&D, doubling planned Phase 3 trial starts this year from 10 to more than 20.
Read more →Sanofi Kills the Drug That Was Supposed to Replace Its $11B Blockbuster
Sanofi axed amlitelimab, the next-gen eczema drug acquired through a deal worth up to $1.45 billion, after it failed to meaningfully outperform the company's own Dupixent in Phase 3 trials. With Dupixent's core U.S. patent protection running through 2031, Sanofi has time to find a replacement, but its most advanced successor candidate just became a celiac disease side project.
Read more →Clinical and Regulatory
The Only Drug That Prevents Congenital Syphilis Is Disappearing From Shelves
Pfizer recalled lots of Bicillin L-A, the sole recommended treatment for syphilis in pregnant women, after particulates were found in prefilled syringes. The recall compounds a shortage lasting since 2023, with full supply recovery not expected until late 2026 at the earliest. Congenital syphilis hit nearly 4,000 cases in 2024, and there is literally no alternative drug for pregnant patients.
Read more →FDA's Drug Review Center Has Lost One in Five Employees Since Early 2025
CDER shed roughly 1,093 employees in fiscal year 2025 and has cycled through five directors since January of that year. As of Q1 of fiscal 2026, CDER's user-fee hiring goals for drug and biosimilar reviews were set at zero FTEs. The center still approved 46 novel drugs last year, but analysts warn institutional knowledge is eroding faster than headcount numbers suggest.
Read more →FDA Panel Reviews First Heart-Targeted Cell Therapy for Duchenne, but Agency Staff Aren't Convinced
The FDA's advisory committee met to review Capricor's deramiocel for Duchenne muscular dystrophy cardiomyopathy, with a final decision due August 22. The agency's own briefing document said "the evidence does not demonstrate efficacy," noting the pivotal trial's primary endpoint measured arm function, not heart function. Patients showed 54% slower upper limb decline and 91% slower cardiac decline versus placebo.
Read more →Science and Discovery
Roche Kills Two Huntington's Programs on the Same Day, Including a Decade-Long Ionis Partnership
Roche terminated both tominersen (developed with Ionis) and its next-gen follow-up RG6496 for Huntington's disease. Tominersen successfully lowered the toxic protein in patients' spinal fluid but showed no clinical improvement over placebo. The double termination adds to a brutal string of Huntington's drug failures and raises hard questions about whether lowering huntingtin protein alone is enough.
Read more →Genetic Markers Could Predict Who Gets Wrecked by CAR-T Therapy
Researchers identified inherited genetic markers that predict severe side effects from Yescarta, where 78% of patients experience some neurological toxicity. Mutations in the HLH-related gene STXBP2 were enriched in patients with the worst reactions. Pre-treatment genetic screening could eventually sort patients by risk and guide preventive interventions, potentially expanding who's eligible for CAR-T.
Read more →